SFT2D3 Inhibitors
SFT2D3 inhibitors encompass a range of chemical entities designed to interact with various components of the intracellular trafficking system.The chemical inhibitors of vesicle formation, such as Dynasore, which acts on dynamin to prevent vesicle scission. Others, like Brefeldin A and Golgicide A, target the Golgi apparatus, disrupting its structure and function, which is essential for the processing and sorting of proteins for secretion or transport to other cellular destinations. Monensin and Tunicamycin disrupt Golgi function by altering pH levels and inhibiting glycosylation, respectively, leading to misfolded proteins and disrupted trafficking.
Compounds like Nocodazole and Latrunculin A affect the cytoskeleton, an integral component of intracellular transport pathways, by destabilizing microtubules and actin filaments, respectively. Furthermore, substances such as Cytochalasin D and Latrunculin A directly target the actin cytoskeleton, disrupting the polymerization of actin and interfering with the transport of vesicles throughout the cell. ML141 and NSC 23766 inhibit small GTPases CDC42 and Rac1, respectively, which are involved in the regulation of cytoskeletal dynamics and membrane trafficking.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Disrupts the function of ADP-ribosylation factors, leading to Golgi apparatus disassembly, which can impair the trafficking functions of SFT2D3. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $187.00 $670.00 | 11 | |
Selectively inhibits the Golgi BFA resistance factor 1, which can result in Golgi disruption, potentially influencing the activity of SFT2D3. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Ionophore that alters Golgi apparatus pH and cation homeostasis, which can affect protein sorting and trafficking associated with SFT2D3. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Inhibits N-linked glycosylation, which can impair the proper folding and trafficking of glycoproteins, potentially affecting SFT2D3-regulated pathways. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Destabilizes microtubules, which can impede intracellular transport processes, possibly influencing SFT2D3's role in trafficking. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
Inhibits actin polymerization, which can disrupt cytoskeletal functions, potentially affecting vesicular transport activities of SFT2D3. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Inhibits dynamin, which can interfere with the scission of clathrin-coated vesicles, potentially influencing SFT2D3-mediated trafficking. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $260.00 $799.00 | 36 | |
Disrupts microfilaments by binding to actin, which can interfere with cytoskeletal dynamics, potentially affecting SFT2D3 function. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $134.00 $502.00 | 7 | |
CDC42 inhibitor, which can alter cytoskeletal organization, potentially influencing the vesicular trafficking functions of SFT2D3. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
Rac1 inhibitor, which can disrupt actin cytoskeleton organization and membrane ruffling, potentially affecting SFT2D3-mediated processes. | ||||||